Boucher-Neuhauser Syndrome

Mendelian MONDO:0008980 Pathograph 13 Show in embeddings browser Hereditary Ataxia Congenital Hypogonadotropic Hypogonadism

Boucher-Neuhauser syndrome (BNS) is a rare autosomal recessive neurodegenerative disorder caused by biallelic pathogenic variants in PNPLA6, which encodes neuropathy target esterase (NTE). It is classically defined by the triad of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy, and is now recognized as one cluster on a continuous PNPLA6-disorder spectrum that also includes Gordon Holmes syndrome, Oliver-McFarlane syndrome, Laurence-Moon syndrome, and spastic paraplegia type 39. NTE is an endoplasmic-reticulum-associated phospholipase/esterase required for phospholipid (phosphatidylcholine/lysophospholipid) homeostasis; loss of NTE activity causes degeneration of cerebellar, retinal, and hypothalamic-pituitary neurons. Residual NTE activity correlates inversely with the presence of retinopathy and endocrinopathy.

Ask OpenScientist

Ask a research question about Boucher-Neuhauser Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
2
Pathophys.
10
Phenotypes
13
Pathograph
1
Genes
3
Medical Actions
1
References
1
Deep Research
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
BNS is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in PNPLA6 and is inherited in an autosomal recessive manner.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:38683245 SUPPORT Human Clinical
"Boucher Neuhäuser Syndrome (BNS) is a rare disease with autosomal recessive inheritance defined by the classical triad; early-onset ataxia, hypogonadism and chorioretinal dystrophy."
Directly states the autosomal recessive inheritance pattern and the defining clinical triad.
PMID:25299038 SUPPORT Human Clinical
"PNPLA6 disorders are inherited in an autosomal recessive manner."
GeneReviews confirms autosomal recessive inheritance for the PNPLA6 disorder spectrum, which includes BNS.
⚙

Pathophysiology

2
Loss of neuropathy target esterase (NTE) activity
PNPLA6 encodes neuropathy target esterase (NTE), a patatin-like serine hydrolase on the cytoplasmic face of the endoplasmic reticulum with phospholipase/lysophospholipase activity. NTE deacylates glycerophospholipids and is central to phosphatidylcholine homeostasis. Biallelic pathogenic PNPLA6 variants, which cluster in the C-terminal phospholipase/esterase (patatin-like) domain, reduce NTE esterase activity, the principal loss-of-function mechanism underlying BNS.
PNPLA6 hgnc:16268
phospholipid metabolic process GO:0006644 ↓ DECREASED phosphatidylcholine metabolic process GO:0046470 ⚠ ABNORMAL
glycerophospholipase (NTE esterase) activity GO:0004620 ↓ DECREASED carboxylic ester hydrolase activity GO:0052689 ↓ DECREASED
endoplasmic reticulum membrane GO:0005789
Downstream
NTE-activity-dependent neurodegeneration of vulnerable tissues Reduced PNPLA6/NTE esterase activity produces the tissue-vulnerability phenotype continuum across PNPLA6 disorders.
Show evidence (2 references)
PMID:37732399 SUPPORT Human Clinical
"PNPLA6 encodes NTE, an enzyme involved in maintaining phospholipid homeostasis and trafficking in the nervous system."
Establishes NTE's role in phospholipid homeostasis whose disruption is the molecular basis of BNS.
PMID:38735647 SUPPORT Human Clinical
"Measuring esterase activity of 46 disease-associated and 20 common variants observed across PNPLA6-associated clinical diagnoses unambiguously reclassified 36 variants as pathogenic and 10 variants as likely pathogenic"
Demonstrates that disease-associated PNPLA6 variants reduce NTE esterase activity, supporting loss of enzymatic function as the mechanism.
NTE-activity-dependent neurodegeneration of vulnerable tissues
Reduced NTE activity disrupts phospholipid remodeling at ER membranes, rendering specific neuronal and supporting cell populations vulnerable to age-dependent degeneration: cerebellar Purkinje-cell circuits (ataxia), retinal photoreceptors and retinal pigment epithelium (chorioretinal dystrophy), and hypothalamic-pituitary neurons (hypogonadotropic hypogonadism / anterior hypopituitarism). Overall NTE activity is inversely related to the presence of retinopathy and endocrinopathy, defining a genotype:activity:phenotype continuum across PNPLA6 disorders. An allelic mouse series recapitulates an NTE activity threshold for retinal degeneration, with complete loss being embryonic lethal.
cerebellar Purkinje cell CL:0000121 retinal photoreceptor cell CL:0000210 retinal pigment epithelial cell CL:0002586
neuron apoptotic process GO:0051402 ↑ INCREASED
Downstream
Cerebellar ataxia Cerebellar neuronal vulnerability manifests as cerebellar ataxia.
Cerebellar atrophy Cerebellar neurodegeneration is visible as cerebellar atrophy on MRI.
Hypogonadotropic hypogonadism Hypothalamic-pituitary vulnerability manifests as hypogonadotropic hypogonadism.
Anterior hypopituitarism Endocrine involvement can extend from isolated hypogonadotropic hypogonadism to anterior hypopituitarism.
Chorioretinal dystrophy Retinal vulnerability manifests as chorioretinal dystrophy.
Visual impairment Progressive retinal disease causes visual impairment across the PNPLA6 spectrum.
Peripheral axonal neuropathy PNPLA6 neurodegenerative involvement can extend to peripheral axons.
Spasticity Upper-motor-neuron involvement in PNPLA6 disorders can manifest as spasticity.
Cognitive impairment CNS involvement in the PNPLA6 spectrum includes cognitive impairment in a subset of patients.
Nystagmus Cerebellar and ocular involvement can produce nystagmus.
Show evidence (3 references)
PMID:38735647 SUPPORT Human Clinical
"Estimating the overall NTE activity of affected individuals revealed a striking inverse relationship between NTE activity and the presence of retinopathy and endocrinopathy."
Links reduced NTE activity quantitatively to the retinal and endocrine manifestations of the PNPLA6 spectrum that includes BNS.
PMID:38735647 SUPPORT Model Organism
"This phenomenon was recaptured in vivo in an allelic mouse series, where a similar NTE threshold for retinopathy exists."
An allelic mouse series recapitulates the NTE-activity threshold for retinal degeneration, supporting the causal chain in vivo.
PMID:35448471 SUPPORT Model Organism
"A conditional knockout of PNPLA6/NTE in the mouse brain results in age-related neurodegeneration, whereas a complete knockout causes lethality during embryogenesis due to defects in the development of the placenta."
Mouse models show that NTE loss causes age-related neurodegeneration and that complete loss is embryonic lethal, consistent with the human activity-threshold model.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Boucher-Neuhauser Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Endocrine 1
Hypogonadotropic hypogonadism VERY_FREQUENT Hypogonadotropic hypogonadism HP:0000044
Show evidence (2 references)
PMID:25267340 SUPPORT Human Clinical
"Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy."
Identifies hypogonadotropic hypogonadism as a defining component of the BNS triad.
PMID:25299038 SUPPORT Human Clinical
"hypogonadotropic hypogonadism (delayed puberty and lack of secondary sex characteristics)"
GeneReviews describes the clinical presentation of the hypogonadotropic hypogonadism characteristic of BNS.
Eye 3
Chorioretinal dystrophy VERY_FREQUENT Chorioretinal dystrophy HP:0001135
Show evidence (2 references)
PMID:25267340 SUPPORT Human Clinical
"Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy."
Identifies chorioretinal dystrophy as a defining component of the BNS triad.
PMID:37732399 SUPPORT Human Clinical
"Retinal disease presents with a unique chorioretinal dystrophy that is phenotypically similar to choroideremia and Leber congenital amaurosis."
Characterizes the chorioretinal dystrophy and its choroideremia-like appearance in PNPLA6 disorders.
Visual impairment Visual impairment HP:0000505
Show evidence (1 reference)
PMID:38735647 SUPPORT Human Clinical
"Biallelic pathogenic variants in the PNPLA6 gene cause a broad spectrum of disorders leading to gait disturbance, visual impairment, anterior hypopituitarism and hair anomalies."
Lists visual impairment among the cardinal manifestations of PNPLA6 disorders, including BNS.
Nystagmus Nystagmus HP:0000639
Show evidence (1 reference)
PMID:25267340 SUPPORT Human Clinical
"She had hypometric vertical and horizontal saccades, saccadic smooth pursuit, gaze-evoked nystagmus and poor visual suppression of vestibular ocular reflexes."
Documents gaze-evoked nystagmus and saccadic pursuit abnormalities in a molecularly confirmed BNS case.
Musculoskeletal 1
Spasticity OCCASIONAL Spasticity HP:0001257
Show evidence (1 reference)
PMID:25299038 SUPPORT Human Clinical
"upper motor neuron involvement manifesting as spasticity and/or brisk reflexes"
GeneReviews lists spasticity from upper motor neuron involvement among the features of the PNPLA6 spectrum.
Nervous System 3
Cerebellar ataxia VERY_FREQUENT Ataxia HP:0001251
Show evidence (2 references)
PMID:25267340 SUPPORT Human Clinical
"Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy."
Identifies cerebellar ataxia as a defining component of the BNS triad.
PMID:35069422 SUPPORT Human Clinical
"Cerebellar ataxia was observed in seven patients and spastic paraplegia in one patient."
In a cohort of eight biallelic PNPLA6 cases, cerebellar ataxia was present in 7/8, supporting it as a very frequent feature.
Cerebellar atrophy Cerebellar atrophy HP:0001272
Show evidence (2 references)
PMID:35069422 SUPPORT Human Clinical
"Brain MRI showed cerebellar atrophy in 6/8 patients, more pronounced in superior and dorsal vermis lobules (I to VII)."
Documents cerebellar atrophy with characteristic superior/dorsal vermian predominance in PNPLA6 patients.
PMID:31135245 SUPPORT Human Clinical
"Hypogonadotropic hypogonadism and cerebellar vermis hypoplasia by MRI confirmed a diagnosis of Boucher-Neuhäuser syndrome."
Cerebellar vermis involvement on MRI contributed to the BNS diagnosis in a molecularly confirmed case.
Cognitive impairment OCCASIONAL Cognitive impairment HP:0100543
Show evidence (1 reference)
PMID:25299038 SUPPORT Human Clinical
"impaired cognitive functioning (learning disabilities in children; deficits in attention, visuospatial abilities, and recall in adults)"
GeneReviews documents cognitive impairment as a less frequent feature of PNPLA6 disorders.
Other 2
Anterior hypopituitarism OCCASIONAL Anterior hypopituitarism HP:0000830
Show evidence (1 reference)
PMID:25299038 SUPPORT Human Clinical
"The hypogonadotropic hypogonadism occurs either in isolation or as part of anterior hypopituitarism (growth hormone, thyroid hormone, or gonadotropin deficiencies)."
GeneReviews documents that anterior hypopituitarism can accompany the hypogonadotropic hypogonadism in PNPLA6 disorders.
Peripheral axonal neuropathy FREQUENT Peripheral axonal neuropathy HP:0003477
Show evidence (1 reference)
PMID:35069422 SUPPORT Human Clinical
"Additional clinical features included hypogonadotropic hypogonadism (5/8), growth hormone deficiency (2/8), peripheral axonal neuropathy (4/8), cognitive impairment (3/8), chorioretinal dystrophy (2/8)"
Peripheral axonal neuropathy was present in 4/8 PNPLA6 patients in this cohort.
🧬

Genetic Associations

1
PNPLA6 (Loss of function mutation)
Gene: PNPLA6 hgnc:16268
Show evidence (3 references)
PMID:35198007 SUPPORT Human Clinical
"Boucher-Neuhäuser syndrome (BNS, MIM 215470) is a rare autosomal recessive syndrome caused by mutations in the PNPLA6 gene."
Directly identifies PNPLA6 as the causal gene for BNS.
PMID:25267340 SUPPORT Human Clinical
"both mutations (one novel and one known) fell in the phospholipase esterase domain, where most pathogenic mutations seem to cluster"
Documents that pathogenic PNPLA6 variants in BNS cluster in the phospholipase esterase (catalytic) domain.
PMID:35069422 SUPPORT Human Clinical
"A wide spectrum of neurodegenerative diseases has been associated with pathogenic variants in the PNPLA6 (patatin-like phospholipase domain-containing protein 6) gene, including spastic paraplegia type 39, Gordon-Holmes, Boucher-Neuhauser, Oliver-Mc Farlane, and Laurence-Moon syndromes."
Establishes BNS as part of the broader allelic PNPLA6 disorder spectrum.
💊

Medical Actions

3
Hormone replacement therapy
Action: Hormone replacement therapy Ontology label: Hormone Replacement Therapy NCIT:C15599
Management is symptomatic. Hormone replacement therapy is given for the endocrine deficiencies: at the expected time of puberty for hypogonadotropic hypogonadism, during childhood/adolescence for growth hormone deficiency, and as soon as identified for hypothyroidism.
Show evidence (1 reference)
PMID:25299038 SUPPORT Human Clinical
"Hypogonadotropic hypogonadism. Hormone replacement therapy at the expected time of puberty."
GeneReviews recommends hormone replacement therapy for the hypogonadotropic hypogonadism of PNPLA6 disorders.
Supportive and rehabilitative care
Action: supportive care MAXO:0000950
Symptomatic, individually tailored multidisciplinary care: continuous training of speech/swallowing, fine-motor skills, gait, and balance for ataxia; physical therapy, assistive walking devices, and antispasticity measures for spasticity; and low-vision aids and visual rehabilitation for chorioretinal dystrophy. Patients should avoid alcohol, obesity, a sedentary lifestyle, and medications/chemicals that exacerbate neuropathy.
Show evidence (2 references)
PMID:25299038 SUPPORT Human Clinical
"Management is symptomatic and individually tailored. Ataxia. Continuous training of speech and swallowing, fine-motor skills, gait, and balance."
GeneReviews describes the symptomatic, multidisciplinary supportive management of PNPLA6 disorders.
PMID:25299038 SUPPORT Human Clinical
"Agents/circumstances to avoid: Alcohol; obesity; inactive, sedentary lifestyle; exposure to medications or chemicals that exacerbate neuropathy."
GeneReviews lists agents/circumstances to avoid, captured here as part of supportive management guidance.
Genetic counseling
Action: Genetic Counseling NCIT:C15240
Genetic counseling is recommended given autosomal recessive inheritance. Once the familial PNPLA6 variants are known, carrier testing for at-risk relatives, prenatal testing, and preimplantation genetic testing are possible.
Show evidence (1 reference)
PMID:25299038 SUPPORT Human Clinical
"Once the PNPLA6 pathogenic variants in the family have been identified, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible."
GeneReviews describes the genetic-counseling options available for PNPLA6 disorders.
{ }

Source YAML

click to show 
name: Boucher-Neuhauser Syndrome
creation_date: "2026-06-04T12:00:00Z"
category: Mendelian
synonyms:
- BNHS
- Boucher-Neuhäuser syndrome
- Spinocerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy
- Ataxia-hypogonadism-choroidal dystrophy syndrome
description: >-
  Boucher-Neuhauser syndrome (BNS) is a rare autosomal recessive
  neurodegenerative disorder caused by biallelic pathogenic variants in PNPLA6,
  which encodes neuropathy target esterase (NTE). It is classically defined by
  the triad of cerebellar ataxia, hypogonadotropic hypogonadism, and
  chorioretinal dystrophy, and is now recognized as one cluster on a continuous
  PNPLA6-disorder spectrum that also includes Gordon Holmes syndrome,
  Oliver-McFarlane syndrome, Laurence-Moon syndrome, and spastic paraplegia
  type 39. NTE is an endoplasmic-reticulum-associated phospholipase/esterase
  required for phospholipid (phosphatidylcholine/lysophospholipid) homeostasis;
  loss of NTE activity causes degeneration of cerebellar, retinal, and
  hypothalamic-pituitary neurons. Residual NTE activity correlates inversely
  with the presence of retinopathy and endocrinopathy.
disease_term:
  preferred_term: Boucher-Neuhauser syndrome
  term:
    id: MONDO:0008980
    label: ataxia-hypogonadism-choroidal dystrophy syndrome
parents:
- Hereditary Ataxia
- Congenital Hypogonadotropic Hypogonadism
references:
- reference: PMID:25299038
  title: "PNPLA6 Disorders."
  tags:
  - GeneReviews
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    BNS is caused by biallelic (homozygous or compound heterozygous) pathogenic
    variants in PNPLA6 and is inherited in an autosomal recessive manner.
  evidence:
  - reference: PMID:38683245
    reference_title: "Two case reports of a novel missense mutation in the PNPLA6 gene in two siblings with chorioretinal dystrophy, hypogonadotropic hypogonadism, and cerebellar ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Boucher Neuhäuser Syndrome (BNS) is a rare disease with autosomal recessive inheritance defined by the classical triad; early-onset ataxia, hypogonadism and chorioretinal dystrophy.
    explanation: >-
      Directly states the autosomal recessive inheritance pattern and the
      defining clinical triad.
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PNPLA6 disorders are inherited in an autosomal recessive manner.
    explanation: >-
      GeneReviews confirms autosomal recessive inheritance for the PNPLA6
      disorder spectrum, which includes BNS.
pathophysiology:
- name: Loss of neuropathy target esterase (NTE) activity
  description: >-
    PNPLA6 encodes neuropathy target esterase (NTE), a patatin-like serine
    hydrolase on the cytoplasmic face of the endoplasmic reticulum with
    phospholipase/lysophospholipase activity. NTE deacylates glycerophospholipids
    and is central to phosphatidylcholine homeostasis. Biallelic pathogenic
    PNPLA6 variants, which cluster in the C-terminal phospholipase/esterase
    (patatin-like) domain, reduce NTE esterase activity, the principal
    loss-of-function mechanism underlying BNS.
  genes:
  - preferred_term: PNPLA6
    term:
      id: hgnc:16268
      label: PNPLA6
  biological_processes:
  - preferred_term: phospholipid metabolic process
    term:
      id: GO:0006644
      label: phospholipid metabolic process
    modifier: DECREASED
  - preferred_term: phosphatidylcholine metabolic process
    term:
      id: GO:0046470
      label: phosphatidylcholine metabolic process
    modifier: ABNORMAL
  molecular_functions:
  - preferred_term: glycerophospholipase (NTE esterase) activity
    term:
      id: GO:0004620
      label: glycerophospholipase activity
    modifier: DECREASED
  - preferred_term: carboxylic ester hydrolase activity
    term:
      id: GO:0052689
      label: carboxylic ester hydrolase activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: endoplasmic reticulum membrane
    term:
      id: GO:0005789
      label: endoplasmic reticulum membrane
  evidence:
  - reference: PMID:37732399
    reference_title: "PNPLA6 disorders: what's in a name?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PNPLA6 encodes NTE, an enzyme involved in maintaining phospholipid homeostasis and trafficking in the nervous system.
    explanation: >-
      Establishes NTE's role in phospholipid homeostasis whose disruption is the
      molecular basis of BNS.
  - reference: PMID:38735647
    reference_title: "Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Measuring esterase activity of 46 disease-associated and 20 common variants observed across PNPLA6-associated clinical diagnoses unambiguously reclassified 36 variants as pathogenic and 10 variants as likely pathogenic
    explanation: >-
      Demonstrates that disease-associated PNPLA6 variants reduce NTE esterase
      activity, supporting loss of enzymatic function as the mechanism.
  downstream:
  - target: NTE-activity-dependent neurodegeneration of vulnerable tissues
    description: Reduced PNPLA6/NTE esterase activity produces the tissue-vulnerability phenotype continuum across PNPLA6 disorders.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38735647
      reference_title: "Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Estimating the overall NTE activity of affected individuals revealed a striking inverse relationship between NTE activity and the presence of retinopathy and endocrinopathy.
      explanation: Human genotype-function data link lower NTE activity to retinal and endocrine phenotypes.
- name: NTE-activity-dependent neurodegeneration of vulnerable tissues
  description: >-
    Reduced NTE activity disrupts phospholipid remodeling at ER membranes,
    rendering specific neuronal and supporting cell populations vulnerable to
    age-dependent degeneration: cerebellar Purkinje-cell circuits (ataxia),
    retinal photoreceptors and retinal pigment epithelium (chorioretinal
    dystrophy), and hypothalamic-pituitary neurons (hypogonadotropic
    hypogonadism / anterior hypopituitarism). Overall NTE activity is inversely
    related to the presence of retinopathy and endocrinopathy, defining a
    genotype:activity:phenotype continuum across PNPLA6 disorders. An allelic
    mouse series recapitulates an NTE activity threshold for retinal
    degeneration, with complete loss being embryonic lethal.
  cell_types:
  - preferred_term: cerebellar Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  - preferred_term: retinal photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:38735647
    reference_title: "Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Estimating the overall NTE activity of affected individuals revealed a striking inverse relationship between NTE activity and the presence of retinopathy and endocrinopathy.
    explanation: >-
      Links reduced NTE activity quantitatively to the retinal and endocrine
      manifestations of the PNPLA6 spectrum that includes BNS.
  - reference: PMID:38735647
    reference_title: "Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This phenomenon was recaptured in vivo in an allelic mouse series, where a similar NTE threshold for retinopathy exists.
    explanation: >-
      An allelic mouse series recapitulates the NTE-activity threshold for
      retinal degeneration, supporting the causal chain in vivo.
  - reference: PMID:35448471
    reference_title: "PNPLA6/NTE, an Evolutionary Conserved Phospholipase Linked to a Group of Complex Human Diseases."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      A conditional knockout of PNPLA6/NTE in the mouse brain results in age-related neurodegeneration, whereas a complete knockout causes lethality during embryogenesis due to defects in the development of the placenta.
    explanation: >-
      Mouse models show that NTE loss causes age-related neurodegeneration and
      that complete loss is embryonic lethal, consistent with the human
      activity-threshold model.
  downstream:
  - target: Cerebellar ataxia
    description: Cerebellar neuronal vulnerability manifests as cerebellar ataxia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25267340
      reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy.
      explanation: The defining Boucher-Neuhauser triad includes cerebellar ataxia.
  - target: Cerebellar atrophy
    description: Cerebellar neurodegeneration is visible as cerebellar atrophy on MRI.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35069422
      reference_title: "Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Brain MRI showed cerebellar atrophy in 6/8 patients, more pronounced in superior and dorsal vermis lobules (I to VII).
      explanation: PNPLA6 cohort data support cerebellar atrophy as a structural outcome.
  - target: Hypogonadotropic hypogonadism
    description: Hypothalamic-pituitary vulnerability manifests as hypogonadotropic hypogonadism.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25267340
      reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy.
      explanation: The defining Boucher-Neuhauser triad includes hypogonadotropic hypogonadism.
  - target: Anterior hypopituitarism
    description: Endocrine involvement can extend from isolated hypogonadotropic hypogonadism to anterior hypopituitarism.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25299038
      reference_title: "PNPLA6 Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The hypogonadotropic hypogonadism occurs either in isolation or as part of anterior hypopituitarism (growth hormone, thyroid hormone, or gonadotropin deficiencies).
      explanation: GeneReviews supports anterior hypopituitarism as part of the PNPLA6 endocrine phenotype spectrum.
  - target: Chorioretinal dystrophy
    description: Retinal vulnerability manifests as chorioretinal dystrophy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25267340
      reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy.
      explanation: The defining Boucher-Neuhauser triad includes chorioretinal dystrophy.
  - target: Visual impairment
    description: Progressive retinal disease causes visual impairment across the PNPLA6 spectrum.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38735647
      reference_title: "Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Biallelic pathogenic variants in the PNPLA6 gene cause a broad spectrum of disorders leading to gait disturbance, visual impairment, anterior hypopituitarism and hair anomalies.
      explanation: Human PNPLA6-spectrum data support visual impairment as a downstream clinical output.
  - target: Peripheral axonal neuropathy
    description: PNPLA6 neurodegenerative involvement can extend to peripheral axons.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:35069422
      reference_title: "Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Additional clinical features included hypogonadotropic hypogonadism (5/8), growth hormone deficiency (2/8), peripheral axonal neuropathy (4/8), cognitive impairment (3/8), chorioretinal dystrophy (2/8)
      explanation: Cohort data support peripheral axonal neuropathy as a PNPLA6-spectrum feature.
  - target: Spasticity
    description: Upper-motor-neuron involvement in PNPLA6 disorders can manifest as spasticity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25299038
      reference_title: "PNPLA6 Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        upper motor neuron involvement manifesting as spasticity and/or brisk reflexes
      explanation: GeneReviews supports spasticity as an upper-motor-neuron manifestation.
  - target: Cognitive impairment
    description: CNS involvement in the PNPLA6 spectrum includes cognitive impairment in a subset of patients.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25299038
      reference_title: "PNPLA6 Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        impaired cognitive functioning (learning disabilities in children; deficits in attention, visuospatial abilities, and recall in adults)
      explanation: GeneReviews supports cognitive impairment as a PNPLA6-spectrum phenotype.
  - target: Nystagmus
    description: Cerebellar and ocular involvement can produce nystagmus.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25267340
      reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        She had hypometric vertical and horizontal saccades, saccadic smooth pursuit, gaze-evoked nystagmus and poor visual suppression of vestibular ocular reflexes.
      explanation: A molecularly confirmed case supports nystagmus as an oculomotor output.
phenotypes:
- name: Cerebellar ataxia
  category: Phenotypic
  description: >-
    Cerebellar ataxia/cerebellar degeneration is a core feature, with onset
    ranging from childhood to adulthood and typically slow progression; brain
    MRI commonly shows cerebellar (often superior vermian) atrophy.
  phenotype_term:
    preferred_term: Cerebellar ataxia
    term:
      id: HP:0001251
      label: Ataxia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:25267340
    reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy.
    explanation: >-
      Identifies cerebellar ataxia as a defining component of the BNS triad.
  - reference: PMID:35069422
    reference_title: "Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cerebellar ataxia was observed in seven patients and spastic paraplegia in one patient.
    explanation: >-
      In a cohort of eight biallelic PNPLA6 cases, cerebellar ataxia was present
      in 7/8, supporting it as a very frequent feature.
- name: Cerebellar atrophy
  category: Phenotypic
  description: >-
    Brain MRI shows cerebellar atrophy, most pronounced in the superior and
    dorsal vermis.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:35069422
    reference_title: "Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Brain MRI showed cerebellar atrophy in 6/8 patients, more pronounced in superior and dorsal vermis lobules (I to VII).
    explanation: >-
      Documents cerebellar atrophy with characteristic superior/dorsal vermian
      predominance in PNPLA6 patients.
  - reference: PMID:31135245
    reference_title: "Detailed retinal phenotype of Boucher-Neuhäuser syndrome associated with mutations in PNPLA6 mimicking choroideremia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypogonadotropic hypogonadism and cerebellar vermis hypoplasia by MRI confirmed a diagnosis of Boucher-Neuhäuser syndrome.
    explanation: >-
      Cerebellar vermis involvement on MRI contributed to the BNS diagnosis in a
      molecularly confirmed case.
- name: Hypogonadotropic hypogonadism
  category: Phenotypic
  description: >-
    Hypogonadotropic hypogonadism presents as delayed puberty and lack of
    secondary sexual characteristics, with low gonadotropins (LH/FSH). It may
    occur in isolation or as part of broader anterior hypopituitarism.
  phenotype_term:
    preferred_term: Hypogonadotropic hypogonadism
    term:
      id: HP:0000044
      label: Hypogonadotropic hypogonadism
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:25267340
    reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy.
    explanation: >-
      Identifies hypogonadotropic hypogonadism as a defining component of the BNS
      triad.
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      hypogonadotropic hypogonadism (delayed puberty and lack of secondary sex characteristics)
    explanation: >-
      GeneReviews describes the clinical presentation of the hypogonadotropic
      hypogonadism characteristic of BNS.
- name: Anterior hypopituitarism
  category: Phenotypic
  description: >-
    In a subset of patients, hypogonadotropic hypogonadism occurs as part of
    broader anterior hypopituitarism with additional growth hormone, thyroid
    hormone, or gonadotropin deficiencies.
  phenotype_term:
    preferred_term: Anterior hypopituitarism
    term:
      id: HP:0000830
      label: Anterior hypopituitarism
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The hypogonadotropic hypogonadism occurs either in isolation or as part of anterior hypopituitarism (growth hormone, thyroid hormone, or gonadotropin deficiencies).
    explanation: >-
      GeneReviews documents that anterior hypopituitarism can accompany the
      hypogonadotropic hypogonadism in PNPLA6 disorders.
- name: Chorioretinal dystrophy
  category: Phenotypic
  description: >-
    Chorioretinal dystrophy with progressive retinal pigment epithelium and
    choriocapillaris atrophy; onset is widely variable and the presentation can
    closely mimic choroideremia, sometimes progressing to severe visual loss or
    blindness.
  phenotype_term:
    preferred_term: Chorioretinal dystrophy
    term:
      id: HP:0001135
      label: Chorioretinal dystrophy
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:25267340
    reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Boucher-Neuhäuser is a rare autosomal recessive syndrome characterized by the co-occurrence of cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy.
    explanation: >-
      Identifies chorioretinal dystrophy as a defining component of the BNS triad.
  - reference: PMID:37732399
    reference_title: "PNPLA6 disorders: what's in a name?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Retinal disease presents with a unique chorioretinal dystrophy that is phenotypically similar to choroideremia and Leber congenital amaurosis.
    explanation: >-
      Characterizes the chorioretinal dystrophy and its choroideremia-like
      appearance in PNPLA6 disorders.
- name: Visual impairment
  category: Phenotypic
  description: >-
    Progressive chorioretinal degeneration leads to variable visual impairment,
    which may progress to blindness.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:38735647
    reference_title: "Neuropathy target esterase activity defines phenotypes among PNPLA6 disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Biallelic pathogenic variants in the PNPLA6 gene cause a broad spectrum of disorders leading to gait disturbance, visual impairment, anterior hypopituitarism and hair anomalies.
    explanation: >-
      Lists visual impairment among the cardinal manifestations of PNPLA6
      disorders, including BNS.
- name: Peripheral axonal neuropathy
  category: Phenotypic
  description: >-
    A peripheral neuropathy of axonal type (reduced distal reflexes, diminished
    vibratory sensation, and/or distal muscle wasting) is a common but less
    frequent feature; it may be subclinical and detected only on EMG/NCS.
  phenotype_term:
    preferred_term: Peripheral axonal neuropathy
    term:
      id: HP:0003477
      label: Peripheral axonal neuropathy
  frequency: FREQUENT
  evidence:
  - reference: PMID:35069422
    reference_title: "Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional clinical features included hypogonadotropic hypogonadism (5/8), growth hormone deficiency (2/8), peripheral axonal neuropathy (4/8), cognitive impairment (3/8), chorioretinal dystrophy (2/8)
    explanation: >-
      Peripheral axonal neuropathy was present in 4/8 PNPLA6 patients in this
      cohort.
- name: Spasticity
  category: Phenotypic
  description: >-
    Upper motor neuron involvement manifesting as spasticity and/or brisk
    reflexes occurs along the PNPLA6 phenotypic continuum.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      upper motor neuron involvement manifesting as spasticity and/or brisk reflexes
    explanation: >-
      GeneReviews lists spasticity from upper motor neuron involvement among the
      features of the PNPLA6 spectrum.
- name: Cognitive impairment
  category: Phenotypic
  description: >-
    Impaired cognitive functioning (learning disabilities in children; deficits
    in attention, visuospatial abilities, and recall in adults) occurs in a
    subset of patients.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      impaired cognitive functioning (learning disabilities in children; deficits in attention, visuospatial abilities, and recall in adults)
    explanation: >-
      GeneReviews documents cognitive impairment as a less frequent feature of
      PNPLA6 disorders.
- name: Nystagmus
  category: Phenotypic
  description: >-
    Oculomotor abnormalities including gaze-evoked nystagmus and saccadic
    pursuit have been reported.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:25267340
    reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      She had hypometric vertical and horizontal saccades, saccadic smooth pursuit, gaze-evoked nystagmus and poor visual suppression of vestibular ocular reflexes.
    explanation: >-
      Documents gaze-evoked nystagmus and saccadic pursuit abnormalities in a
      molecularly confirmed BNS case.
genetic:
- name: PNPLA6
  association: Loss of function mutation
  notes: >-
    Biallelic (homozygous or compound heterozygous) pathogenic variants in
    PNPLA6 (19p13.2), encoding neuropathy target esterase, cause BNS. Reported
    variants are predominantly missense, with frameshift, splice-altering, and
    nonsense variants also described; missense/in-frame variants are enriched in
    the catalytic phospholipase/esterase (patatin-like) domain. PNPLA6 is also
    the cause of allelic disorders on the same spectrum, including Gordon Holmes
    syndrome, Oliver-McFarlane syndrome, Laurence-Moon syndrome, and spastic
    paraplegia type 39.
  gene_term:
    preferred_term: PNPLA6
    term:
      id: hgnc:16268
      label: PNPLA6
  evidence:
  - reference: PMID:35198007
    reference_title: "Identification of Novel Compound Heterozygous Variants of the PNPLA6 Gene in Boucher-Neuhäuser Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Boucher-Neuhäuser syndrome (BNS, MIM 215470) is a rare autosomal recessive syndrome caused by mutations in the PNPLA6 gene.
    explanation: >-
      Directly identifies PNPLA6 as the causal gene for BNS.
  - reference: PMID:25267340
    reference_title: "Compound heterozygous PNPLA6 mutations cause Boucher-Neuhäuser syndrome with late-onset ataxia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      both mutations (one novel and one known) fell in the phospholipase esterase domain, where most pathogenic mutations seem to cluster
    explanation: >-
      Documents that pathogenic PNPLA6 variants in BNS cluster in the
      phospholipase esterase (catalytic) domain.
  - reference: PMID:35069422
    reference_title: "Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A wide spectrum of neurodegenerative diseases has been associated with pathogenic variants in the PNPLA6 (patatin-like phospholipase domain-containing protein 6) gene, including spastic paraplegia type 39, Gordon-Holmes, Boucher-Neuhauser, Oliver-Mc Farlane, and Laurence-Moon syndromes.
    explanation: >-
      Establishes BNS as part of the broader allelic PNPLA6 disorder spectrum.
diagnosis:
- name: Molecular genetic testing
  description: >-
    Diagnosis is established in a proband with suggestive findings (cerebellar
    ataxia, chorioretinal dystrophy, hypogonadotropic hypogonadism) by
    identifying biallelic PNPLA6 pathogenic variants, typically via whole-exome
    sequencing with Sanger segregation. Functional NTE esterase-activity assays
    are an emerging adjunct for variant classification and phenotype prediction.
  evidence:
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of a PNPLA6 disorder is established in a proband with suggestive findings and biallelic PNPLA6 pathogenic variants identified on homologous alleles by molecular genetic testing.
    explanation: >-
      GeneReviews describes the molecular diagnostic approach for PNPLA6
      disorders, including BNS.
  - reference: PMID:35198007
    reference_title: "Identification of Novel Compound Heterozygous Variants of the PNPLA6 Gene in Boucher-Neuhäuser Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Gene sequencing is currently the primary diagnostic method.
    explanation: >-
      Confirms gene sequencing as the primary diagnostic modality for BNS.
treatments:
- name: Hormone replacement therapy
  description: >-
    Management is symptomatic. Hormone replacement therapy is given for the
    endocrine deficiencies: at the expected time of puberty for hypogonadotropic
    hypogonadism, during childhood/adolescence for growth hormone deficiency, and
    as soon as identified for hypothyroidism.
  treatment_term:
    preferred_term: Hormone replacement therapy
    term:
      id: NCIT:C15599
      label: Hormone Replacement Therapy
  evidence:
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypogonadotropic hypogonadism. Hormone replacement therapy at the expected time of puberty.
    explanation: >-
      GeneReviews recommends hormone replacement therapy for the hypogonadotropic
      hypogonadism of PNPLA6 disorders.
- name: Supportive and rehabilitative care
  description: >-
    Symptomatic, individually tailored multidisciplinary care: continuous
    training of speech/swallowing, fine-motor skills, gait, and balance for
    ataxia; physical therapy, assistive walking devices, and antispasticity
    measures for spasticity; and low-vision aids and visual rehabilitation for
    chorioretinal dystrophy. Patients should avoid alcohol, obesity, a sedentary
    lifestyle, and medications/chemicals that exacerbate neuropathy.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Management is symptomatic and individually tailored. Ataxia. Continuous training of speech and swallowing, fine-motor skills, gait, and balance.
    explanation: >-
      GeneReviews describes the symptomatic, multidisciplinary supportive
      management of PNPLA6 disorders.
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Agents/circumstances to avoid: Alcohol; obesity; inactive, sedentary lifestyle; exposure to medications or chemicals that exacerbate neuropathy.
    explanation: >-
      GeneReviews lists agents/circumstances to avoid, captured here as part of
      supportive management guidance.
- name: Genetic counseling
  description: >-
    Genetic counseling is recommended given autosomal recessive inheritance.
    Once the familial PNPLA6 variants are known, carrier testing for at-risk
    relatives, prenatal testing, and preimplantation genetic testing are
    possible.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:25299038
    reference_title: "PNPLA6 Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Once the PNPLA6 pathogenic variants in the family have been identified, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible.
    explanation: >-
      GeneReviews describes the genetic-counseling options available for PNPLA6
      disorders.
datasets: []
📚

References & Deep Research

References

1
PMID:25299038
PNPLA6 Disorders.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 25 citations 2026-06-04T11:23:53.735110

1. Disease Information

1.1 What is the disease?

BNS is a multisystem neurodegenerative syndrome that presents with the triad: - Cerebellar ataxia / cerebellar degeneration - Hypogonadotropic hypogonadism (HH) (often described clinically within anterior hypopituitarism) - Chorioretinal dystrophy / retinal degeneration

Primary literature defines BNS as “the triad of early-onset autosomal recessive cerebellar ataxia (ARCA), hypogonadotropic hypogonadism, and chorioretinal dystrophy.” (deik2014compoundheterozygouspnpla6 pages 1-2)

1.2 Key identifiers

  • OMIM/MIM (disease): MIM #215470 (Boucher–Neuhäuser syndrome) (deik2014compoundheterozygouspnpla6 pages 1-2, he2022identificationofnovel pages 1-2)
  • OMIM/MIM (gene): PNPLA6 MIM *603197 (deik2014compoundheterozygouspnpla6 pages 1-2)
  • Other identifiers requested (Orphanet/ICD-10/ICD-11/MeSH/MONDO): Not found in the retrieved full-text excerpts; therefore cannot be asserted from this evidence set. (deik2014compoundheterozygouspnpla6 pages 1-2, he2022identificationofnovel pages 1-2)

1.3 Synonyms / alternative names

  • BNS (common abbreviation) (he2022identificationofnovel pages 1-2, liampas2024twocasereports pages 1-5)
  • Orthographic variants: Boucher–Neuhäuser, Boucher–Neuha¨user (deik2014compoundheterozygouspnpla6 pages 1-2)
  • Historical phenotype description: “familial ataxia, hypogonadism and retinal degeneration” (reported as a historical descriptor in reviews of PNPLA6 phenotypes) (nanetti2022multifacetedandagedependent pages 9-10)
  • Related/overlapping entities within PNPLA6 disorders: Gordon Holmes syndrome and others (deik2014compoundheterozygouspnpla6 pages 1-2, he2022identificationofnovel pages 1-2, liu2023pnpla6disorderswhat’s pages 3-4)

1.4 Evidence type (individual vs aggregated)

Evidence base is largely case reports/series aggregated in systematic reviews and cohort meta-analyses, including a large integrated dataset of published individuals with biallelic PNPLA6 variants (95 as of May 2023) and an expanded cohort of 118 individuals in later functional-genotype studies. (liu2023pnpla6disorderswhat’s pages 3-4, liu2024neuropathytargetesterase pages 4-6)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants in PNPLA6, encoding neuropathy target esterase (NTE). BNS is repeatedly described as “a rare autosomal recessive syndrome caused by mutations in the PNPLA6 gene.” (he2022identificationofnovel pages 1-2)

Mechanistic framing: PNPLA6/NTE is an ER-associated patatin-like phospholipase/esterase involved in phospholipid homeostasis and trafficking; loss-of-function is supported by animal/cellular models. (liu2023pnpla6disorderswhat’s pages 1-3)

2.2 Risk factors

  • Genetic risk: having biallelic pathogenic PNPLA6 variants (autosomal recessive). (he2022identificationofnovel pages 1-2, deik2014compoundheterozygouspnpla6 pages 2-5)
  • Consanguinity can increase risk of homozygous variants (illustrated by affected siblings from a consanguineous family). (liampas2024twocasereports pages 1-5)

No environmental, infectious, or lifestyle risk factors specific to BNS were identified in the retrieved evidence.

2.3 Protective factors

No genetic or environmental protective factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

Direct gene–environment interaction evidence for BNS is not present in the retrieved texts. Mechanistically, PNPLA6/NTE is historically linked to organophosphate-induced delayed neuropathy (OPIDN), which establishes environmental inhibition of NTE as neurotoxic, but this is not evidence of a specific GxE interaction for Mendelian BNS. (liu2023pnpla6disorderswhat’s pages 8-9)

3. Phenotypes

3.1 Core phenotype triad (with suggested HPO terms)

1) Cerebellar ataxia / cerebellar degeneration - Characteristics: variable onset (childhood to adulthood), often slowly progressive; MRI may show superior vermian/cerebellar atrophy. (deik2014compoundheterozygouspnpla6 pages 2-5, nanetti2022multifacetedandagedependent pages 3-5) - Suggested HPO: HP:0001251 (Ataxia); HP:0001272 (Cerebellar atrophy)

2) Hypogonadotropic hypogonadism / anterior hypopituitarism - Characteristics: may be recognized in the first two decades; hormone testing often shows low gonadotropins (LH/FSH) and broader pituitary hormone issues in the PNPLA6 spectrum. (deik2014compoundheterozygouspnpla6 pages 2-5, liampas2024twocasereports pages 1-5, liu2023pnpla6disorderswhat’s pages 3-4) - Suggested HPO: HP:0000044 (Hypogonadotropic hypogonadism); HP:0000871 (Hypopituitarism)

3) Chorioretinal dystrophy / retinal degeneration - Characteristics: onset widely variable (reported 1–64 years across PNPLA6 disorders); may mimic choroideremia; progression can lead to severe vision loss/blindness. (o’neil2019detailedretinalphenotype pages 6-7, liampas2024twocasereports pages 1-5, liu2023pnpla6disorderswhat’s pages 3-4) - Suggested HPO: HP:0000510 (Chorioretinal dystrophy); HP:0000546 (Retinal dystrophy); HP:0000505 (Visual impairment)

3.2 Additional, variably present features

  • Peripheral axonal neuropathy (less common in some BNS descriptions; present in cohorts of PNPLA6 disorders). (liampas2024twocasereports pages 1-5, nanetti2022multifacetedandagedependent pages 3-5)
  • HPO: HP:0003477 (Axonal neuropathy)
  • Oculomotor abnormalities (e.g., gaze-evoked nystagmus, saccadic pursuit) reported in case descriptions. (deik2014compoundheterozygouspnpla6 pages 2-5)
  • HPO: HP:0000639 (Nystagmus)
  • Cognitive impairment observed in a subset of PNPLA6 cohort cases. (nanetti2022multifacetedandagedependent pages 3-5)
  • HPO: HP:0100543 (Cognitive impairment)
  • Hair anomalies occur in a minority of PNPLA6 disorders (more characteristic of Oliver–McFarlane end of spectrum). (liu2023pnpla6disorderswhat’s pages 3-4)
  • HPO examples: HP:0002213 (Trichomegaly), HP:0001596 (Alopecia)

3.3 Frequency / statistics (best available from retrieved sources)

  • Review-level counts: 95 published individuals with biallelic PNPLA6 variants as of May 2023 (PNPLA6 disorders overall). (liu2023pnpla6disorderswhat’s pages 3-4)
  • Cerebellar atrophy/ataxia in up to ~90% of reported PNPLA6 cases. (liu2023pnpla6disorderswhat’s pages 3-4)
  • Case-series (8 novel PNPLA6 cases): 7/8 progressive cerebellar syndrome; 5/8 HH; 2/8 chorioretinal dystrophy; 4/8 peripheral axonal neuropathy and/or spasticity; 3/8 cognitive impairment. (nanetti2022multifacetedandagedependent pages 3-5)

3.4 Quality of life impact

Direct QoL instrument results (EQ-5D/SF-36/PROMIS) were not found in the retrieved texts. Based on clinical manifestations, major impacts include mobility limitations from ataxia and disability from progressive visual loss. (liampas2024twocasereports pages 1-5, liu2023pnpla6disorderswhat’s pages 3-4)

4. Genetic / Molecular Information

4.1 Causal gene(s)

  • PNPLA6 (patatin-like phospholipase domain-containing protein 6), encoding NTE. (he2022identificationofnovel pages 1-2, liu2023pnpla6disorderswhat’s pages 1-3)

4.2 Pathogenic variants (examples from primary literature)

BNS is caused by biallelic PNPLA6 variants (homozygous or compound heterozygous). Examples in retrieved sources include: - Compound heterozygous PNPLA6 mutations (e.g., p.Ser1045Leu and p.Ser1173Arg) in a genetically confirmed BNS case with late-onset ataxia. (deik2014compoundheterozygouspnpla6 pages 2-5) - Compound heterozygous variants including a frameshift and missense in a BNS case with predominantly retinal presentation (p.Arg1031GlnfsTer38 / p.Arg1183Gln). (o’neil2019detailedretinalphenotype pages 6-7) - Novel compound heterozygous variants identified by WES (c.2241del/p.Met748TrpfsTer65 and c.2986A>G/p.Thr996Ala) with RNA-level validation showing decreased PNPLA6 mRNA. (he2022identificationofnovel pages 1-2) - Homozygous missense c.3323G>A (p.Arg1108Gln) in two siblings. (liampas2024twocasereports pages 1-5)

Variant types reported across PNPLA6 disorders include missense, frameshift, splice-altering, and nonsense variants. In the Brain 2024 systematic cohort, 106 unique variants were summarized (70 missense; 35 predicted loss-of-function; 1 in-frame deletion), with enrichment of missense/in-frame variants in the catalytic domain. (liu2024neuropathytargetesterase pages 4-6)

4.3 Functional consequences

Multiple sources support loss-of-function as a principal mechanism, operationalized as reduced NTE hydrolase/esterase activity for many disease-associated variants. (liu2023pnpla6disorderswhat’s pages 1-3, liu2023neuropathytargetesterase pages 1-6)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No modifier genes, epigenetic signatures, or chromosomal abnormalities specific to BNS were identified in the retrieved evidence.

5. Environmental Information

No validated non-genetic environmental causes of Mendelian BNS were identified in the retrieved sources. However, PNPLA6/NTE is historically implicated in organophosphate neurotoxicity (OPIDN), indicating that environmental inhibition of NTE is neurotoxic in other contexts and motivates biomarker measurement in exposure studies. (liu2023pnpla6disorderswhat’s pages 8-9, NCT00671866 chunk 1)

6. Mechanism / Pathophysiology

6.1 Molecular function and pathways

PNPLA6 encodes NTE, described as a patatin-like serine hydrolase on the cytoplasmic face of the ER with: - Phospholipase B activity (deacylation of glycerophospholipids) - Strong lysophospholipase activity - Roles in phosphatidylcholine (PC) homeostasis (CDP-choline/Kennedy pathway), membrane trafficking, and axonal integrity. (liu2023pnpla6disorderswhat’s pages 1-3)

Suggested GO terms (biological process / molecular function; provisional) - GO:0006644 (phospholipid metabolic process) - GO:0004620 (phospholipase activity) - GO:0047499 (phospholipase B activity) - GO:0052689 (carboxylic ester hydrolase activity) - GO:0005789 (endoplasmic reticulum membrane; cellular component)

6.2 Causal chain (conceptual)

1) Biallelic PNPLA6 variants → 2) Reduced NTE enzymatic activity and disrupted phospholipid remodeling/homeostasis at ER membranes → 3) tissue vulnerability in retina (photoreceptors/RPE), cerebellum (Purkinje cell systems), and pituitary–gonadal axis → 4) clinical triad of retinopathy, ataxia, hypogonadotropic hypogonadism.

A key 2024 advance is that residual NTE activity can be used as a quantitative intermediate phenotype that predicts retinopathy and endocrinopathy risk. (liu2024neuropathytargetesterase pages 1-2, liu2024neuropathytargetesterase pages 7-9)

6.3 Recent (2023–2024) genotype:activity:phenotype relationships

In Brain (May 2024), Liu et al. report: - Cohort: 23 new + 95 reported individuals. (liu2024neuropathytargetesterase pages 1-2) - Variant functional assay: measured esterase activity for 46 disease-associated and 20 common variants; reclassified 36 as pathogenic and 10 as likely pathogenic. (liu2024neuropathytargetesterase pages 1-2) - Clinical subtype activity differences: SPG39 mean residual activity ~51% (n=12) vs BNHS ~28% (n=19) and OMCS/LNMS ~28% (n=26). (liu2024neuropathytargetesterase pages 4-6) - Mouse allelic series: <40% NTE activity was embryonic lethal; retinal degeneration onset ~40–50% residual activity. (liu2024neuropathytargetesterase pages 7-9)

These results support expert interpretation that PNPLA6 syndromic labels represent a continuum and that functional enzyme activity can serve both diagnostic and prognostic roles, potentially enabling trial stratification. (liu2024neuropathytargetesterase pages 1-2)

6.4 Model organism evidence (authoritative sources)

  • Chickens (OPIDN): OPIDN requires ~70% inhibition of NTE activity via “aging.” (liu2023pnpla6disorderswhat’s pages 8-9)
  • Drosophila (swiss-cheese; sws): sws loss causes rapid age-dependent neurodegeneration with ~20% more PC, ER stress signatures, and partial rescue by TUDCA (ER stress inhibitor). (liu2023pnpla6disorderswhat’s pages 8-9)
  • Mouse: global Pnpla6 knockout embryonic lethal; neuronal conditional KO shows hippocampal vacuolization, neuronal loss (including Purkinje cells) and axonal lesions. (liu2023pnpla6disorderswhat’s pages 8-9)

Suggested CL terms (cell types; provisional) - Purkinje cell: CL:0000121 - Retinal photoreceptor cell: CL:0000210 - Retinal pigment epithelial cell: CL:0000088

7. Anatomical Structures Affected

Organ/system level (with UBERON suggestions; provisional)

  • Cerebellum (UBERON:0002037) (deik2014compoundheterozygouspnpla6 pages 2-5, liu2023pnpla6disorderswhat’s pages 3-4)
  • Retina / choroid / RPE (UBERON:0000966 for retina; RPE is part of eye tissues) (o’neil2019detailedretinalphenotype pages 6-7, liu2023pnpla6disorderswhat’s pages 3-4)
  • Pituitary gland / hypothalamic–pituitary axis (UBERON:0000007 for pituitary) (liu2023pnpla6disorderswhat’s pages 3-4)

Subcellular localization

  • Endoplasmic reticulum membrane (GO:0005789) for PNPLA6/NTE. (liu2023pnpla6disorderswhat’s pages 1-3)

8. Temporal Development

Onset

Across PNPLA6 disorders (including BNS): - Gait disturbance: 1–55 years - Visual impairment: 1–64 years - Anterior hypopituitarism: birth–25 years - Hair anomalies: birth–18 years

These ranges reflect substantial heterogeneity and age-dependent penetrance of sub-phenotypes. (liu2023pnpla6disorderswhat’s pages 3-4)

Progression

Progression can be slow: - In an 8-patient PNPLA6 series, cerebellar symptoms had mean onset 31 years (range 9–55) and were “very slow” in progression; most had progressive cerebellar syndrome. (nanetti2022multifacetedandagedependent pages 3-5)

9. Inheritance and Population

Inheritance

  • Autosomal recessive inheritance due to biallelic PNPLA6 variants is consistently reported. (he2022identificationofnovel pages 1-2, liampas2024twocasereports pages 1-5)

Epidemiology

No prevalence/incidence per population was identified in the retrieved full texts. Best available “epidemiology-like” statistic is literature case count: - 95 published individuals with biallelic PNPLA6 variants (as of May 2023). (liu2023pnpla6disorderswhat’s pages 3-4)

Population genetics

No carrier frequency estimates or founder variants were identified in the retrieved evidence.

10. Diagnostics

10.1 Clinical tests / evaluations used in practice

Across case reports and reviews, diagnosis is typically assembled from multisystem evaluation: - Brain MRI: cerebellar atrophy, often vermian/superior cerebellar involvement. (deik2014compoundheterozygouspnpla6 pages 2-5, nanetti2022multifacetedandagedependent pages 3-5) - Ophthalmology: fundus exam, OCT, ERG, visual fields/perimetry; can reveal outer retinal loss and chorioretinal atrophy; presentations may mimic choroideremia, necessitating careful differential diagnosis. (deik2014compoundheterozygouspnpla6 pages 2-5, o’neil2019detailedretinalphenotype pages 6-7) - Endocrine testing: gonadotropins (LH/FSH), sex steroids; broader pituitary hormone panels depending on presentation. (deik2014compoundheterozygouspnpla6 pages 2-5, he2022identificationofnovel pages 1-2) - Neurophysiology: EMG/NCS for mild/subclinical axonal neuropathy. (deik2014compoundheterozygouspnpla6 pages 2-5)

10.2 Genetic testing

  • Whole-exome sequencing (WES) with segregation testing is commonly used; authors explicitly state “Gene sequencing is currently the primary diagnostic method.” (he2022identificationofnovel pages 1-2)
  • Emerging 2024 evidence supports adding functional NTE activity assays for variant classification and phenotype prediction. (liu2024neuropathytargetesterase pages 1-2)

10.3 Differential diagnosis

Not comprehensively enumerated in retrieved texts. One practical point is that PNPLA6-associated chorioretinal dystrophy can mimic choroideremia-like presentations, and thus PNPLA6 should be considered in diffuse chorioretinal atrophies with subtle systemic signs. (o’neil2019detailedretinalphenotype pages 6-7)

11. Outcome / Prognosis

Quantitative survival/life expectancy estimates were not found in the retrieved evidence.

Best available natural-history/prognosis statements: - Vision: chorioretinal dystrophy “leads to variable decreased visual acuity, even blindness.” (liampas2024twocasereports pages 1-5) - Some PNPLA6 disorders (milder spectrum) retain ambulation into adulthood with minimal/moderate aid. (liu2023pnpla6disorderswhat’s pages 3-4) - Slow progression of cerebellar syndrome has been reported with long disease duration in case series. (nanetti2022multifacetedandagedependent pages 3-5)

12. Treatment

No disease-modifying therapy is established in the retrieved evidence. Management is supportive and multidisciplinary.

12.1 Pharmacotherapy / endocrine replacement

  • Case report supportive regimen included hormone replacement therapy and vitamin supplementation (B12, C, E). (liampas2024twocasereports pages 1-5)

Suggested MAXO terms (provisional) - MAXO:0000258 (Hormone replacement therapy) - MAXO:0000747 (Vitamin supplementation)

12.2 Rehabilitation / supportive care

Direct rehabilitation trial data were not present in the retrieved texts. Based on multi-system involvement, supportive care typically includes neurology/ataxia management, vision support, and endocrine replacement/surveillance. (liu2023pnpla6disorderswhat’s pages 3-4, liampas2024twocasereports pages 1-5)

12.3 Experimental/clinical trials

No BNS-specific interventional trials were identified in the retrieved clinical-trials search. - An observational trial on organophosphate exposure measures NTE biomarkers but is not a therapeutic trial for BNS and lists “Peripheral Neuropathy” as condition (NCT00671866). (NCT00671866 chunk 1)

13. Prevention

No primary prevention exists for Mendelian BNS beyond reproductive/genetic counseling.

Secondary prevention conceptually includes: - Early recognition of retinal degeneration and pituitary hormone deficiencies for timely supportive interventions. (o’neil2019detailedretinalphenotype pages 6-7, liu2023pnpla6disorderswhat’s pages 3-4)

14. Other Species / Natural Disease

Naturally occurring BNS as a veterinary entity was not identified in the retrieved evidence.

However, PNPLA6 is evolutionarily conserved with an orthologue in Drosophila (swiss-cheese; sws) used to model neurodegeneration and lipid dysregulation. (liu2023pnpla6disorderswhat’s pages 8-9)

15. Model Organisms

Key models and how they recapitulate disease biology

  • Drosophila sws mutants: age-dependent neurodegeneration, altered phospholipids, ER stress; partial pharmacologic rescue (TUDCA). (liu2023pnpla6disorderswhat’s pages 8-9)
  • Mouse Pnpla6 allelic series (2024): demonstrates activity thresholds for viability and retinal degeneration and provides translational evidence for NTE activity as a biomarker. (liu2024neuropathytargetesterase pages 7-9)

Recent developments and expert analysis (2023–2024)

Conceptual shift: discrete syndromes → continuous PNPLA6 spectrum

A 2023 ophthalmic-genetics review frames PNPLA6-related conditions (including BNS) as “PNPLA6-opathies” across a spectrum and highlights a choroideremia-like retinal phenotype and multisystem involvement requiring integrated diagnosis. (liu2023pnpla6disorderswhat’s pages 3-4)

Functional stratification: NTE activity as diagnostic/prognostic biomarker (2024)

The 2024 Brain study provides a quantitative model linking biallelic genotype to residual NTE activity and to the probability of retinopathy/endocrinopathy, and proposes NTE as a biomarker “paving the way for therapeutic trials.” (liu2024neuropathytargetesterase pages 1-2)

Figure evidence supporting these claims is available from cropped panels showing (i) variant domain associations with retinopathy/endocrinopathy and (ii) activity-phenotype correlations and (iii) activity thresholds for retinopathy in vivo. (liu2024neuropathytargetesterase media cbbab372, liu2024neuropathytargetesterase media f1acab95, liu2024neuropathytargetesterase media d77bd8b8)

Key sources table (prioritizing 2023–2024)

Year Citation (first author, journal) Study type (review/case series/mechanistic) Key contributions for BNS (definition/triad; cohort size; key stats like NTE activity means/thresholds; diagnostic insights) URL/DOI Notes (PMID if known—leave blank if not present in text)
2024 Liu, Brain Mechanistic + cohort + systematic review PNPLA6 disorders placed on a continuous spectrum including Boucher–Neuhäuser syndrome (BNHS). Cohort: 23 new patients + 95 previously reported individuals. Functional assay measured 46 disease-associated and 20 common variants; 36 variants reclassified as pathogenic and 10 as likely pathogenic. Synthetic residual NTE activity differed by phenotype: SPG39 mean ~51% (n=12) vs BNHS ~28% (n=19) and OMCS/LNMS ~28% (n=26); lower activity associated with retinopathy/endocrinopathy, with reported threshold-type observations for endocrine/ophthalmic disease below ~32% and retinal degeneration around 40–50% residual activity; mouse data supported retinopathy threshold and embryonic lethality below 40% activity. Supports NTE activity as a biomarker for therapeutic trials. (liu2024neuropathytargetesterase pages 1-2, liu2024neuropathytargetesterase pages 4-6, liu2023neuropathytargetesterase pages 10-14, liu2024neuropathytargetesterase pages 7-9) https://doi.org/10.1093/brain/awae055
2023 Liu, Ophthalmic Genetics Review Defines five PNPLA6 disorders, including Boucher–Neuhäuser syndrome. States PNPLA6/NTE is involved in phospholipid homeostasis and trafficking; animal and cellular models support loss-of-function. As of May 2023, 95 published individuals with biallelic PNPLA6 variants. Cerebellar atrophy/ataxia reported in up to ~90% of cases. BNHS distinguished from Gordon–Holmes by added chorioretinal dystrophy. Diagnostic insights: neurological imaging for cerebellar atrophy, ERG/retinal imaging/visual fields for chorioretinal dystrophy, hormonal testing for anterior hypopituitarism, and exam for hair anomalies. (liu2023pnpla6disorderswhat’s pages 3-4, liu2023pnpla6disorderswhat’s pages 4-6, liu2023pnpla6disorderswhat’s pages 1-3) https://doi.org/10.1080/13816810.2023.2254830
2024 Liampas, Molecular Biology Reports Case reports Two siblings with a novel homozygous PNPLA6 missense variant. Reiterates classical BNS triad: hypogonadotropic hypogonadism, spinocerebellar ataxia, and chorioretinal dystrophy; notes peripheral axonal neuropathy can occur. Provides temporal guidance: HH often in first two decades; ataxia usually before early adulthood but can be late; chorioretinal dystrophy usually before age 50 and may progress to severe visual loss/blindness. Diagnostic workup included MRI, ophthalmologic assessment, endocrine evaluation, electrophysiology, WES and Sanger segregation. (liampas2024twocasereports pages 1-5) https://doi.org/10.1007/s11033-024-09515-4
2022 He, Frontiers in Genetics Case report + variant analysis/systematic review Defines BNS as a rare autosomal recessive PNPLA6 disorder with the triad of cerebellar ataxia, chorioretinal dystrophy, and hypogonadotropic hypogonadism; gives MIM 215470. Reports a 17-year-old with progressive night blindness from age 4, primary amenorrhea, absent secondary sexual development, retinal pigmentary degeneration, and CHH without current ataxia. Identified compound heterozygous PNPLA6 variants by WES; RT-PCR showed reduced PNPLA6 mRNA. Diagnostic insight: detailed ophthalmic exam, endocrine panels, pituitary/pelvic imaging, bone age X-ray, WES/Sanger; authors note gene sequencing is currently the primary diagnostic method. (he2022identificationofnovel pages 1-2) https://doi.org/10.3389/fgene.2022.810537
2022 Nanetti, Frontiers in Neurology Case series + literature review Reviews age-dependent PNPLA6 phenotypes and includes BN presentations. Across eight new PNPLA6 cases: 7/8 had cerebellar ataxia, 5/8 hypogonadotropic hypogonadism, 2/8 chorioretinal dystrophy; cerebellar symptoms mean onset 31 years (range 9–55) with very slow progression. Notes early-onset presentations may start with chorioretinal dystrophy, juvenile cases with HH, adult cases with ataxia. MRI may show cerebellar atrophy (often superior/dorsal vermis) and severe cerebellar atrophy in BN cases. Recommends multidisciplinary assessment and PNPLA6 screening in late-onset/cANVAS-like ataxia when RFC1 expansions are absent. (nanetti2022multifacetedandagedependent pages 9-10, nanetti2022multifacetedandagedependent pages 3-5) https://doi.org/10.3389/fneur.2021.793547
2019 O’Neil, Ophthalmic Genetics Deep phenotyping case report Shows that PNPLA6-associated BNS may present with predominantly retinal findings and subtle systemic abnormalities, mimicking choroideremia. Ophthalmic workup included SD-OCT, ERG, kinetic fields, autofluorescence imaging; systemic confirmation came from hypogonadotropic hypogonadism and cerebellar vermis hypoplasia on MRI. Highlights the need to consider PNPLA6/BNS in diffuse chorioretinal atrophies and to combine ophthalmic phenotyping with systemic review and genetic testing. (o’neil2019detailedretinalphenotype pages 6-7) https://doi.org/10.1080/13816810.2019.1605392
2014 Deik, Journal of Neurology Case report + genetics Landmark report confirming compound heterozygous PNPLA6 mutations as a cause of BNS with late-onset ataxia. Uses MIM #215470 for BNS and emphasizes the triad of autosomal recessive cerebellar ataxia, hypogonadotropic hypogonadism, and chorioretinal dystrophy. Diagnostic workup included fundoscopy/OCT, ERG, visual fields, endocrine testing (low LH/FSH), brain MRI showing superior cerebellar/vermian atrophy, EMG/NCS showing mild distal axonal neuropathy, and PNPLA6 sequencing. Also notes possible cognitive involvement and subclinical polyneuropathy. (deik2014compoundheterozygouspnpla6 pages 11-12, deik2014compoundheterozygouspnpla6 pages 2-5, deik2014compoundheterozygouspnpla6 pages 1-2) https://doi.org/10.1007/s00415-014-7516-3
2022 Kretzschmar, Metabolites Mechanistic review Reviews PNPLA6/NTE as an evolutionarily conserved phospholipase first linked to organophosphate-induced delayed neuropathy and later to inherited disorders including BNS. Summarizes normal role in lipid homeostasis and model-system evidence: mouse brain conditional knockout causes age-related neurodegeneration, complete knockout is embryonic lethal, and Drosophila swiss-cheese loss causes progressive locomotor defects and neurodegeneration. Useful for mechanistic context underlying BNS/PNPLA6 loss-of-function. (liu2023pnpla6disorderswhat’s pages 8-9) https://doi.org/10.3390/metabo12040284

Table: This table summarizes the most useful recent and foundational sources for Boucher–Neuhäuser syndrome within the broader PNPLA6 disorder spectrum. It highlights how each paper contributes evidence on definition, genotype–phenotype correlations, diagnostics, and mechanistic understanding.

Direct abstract quotes (as available in retrieved context)

  • He et al. 2022 (Frontiers in Genetics) abstract includes: “Boucher–Neuhäuser syndrome (BNS, MIM 215470) is a rare autosomal recessive syndrome caused by mutations in the PNPLA6 gene.” (he2022identificationofnovel pages 1-2)
  • O’Neil et al. 2019 abstract includes: “PNPLA6-associated retinal degenerations can present with predominantly retinal findings and subtle systemic abnormalities and should be considered in the differential diagnosis of diffuse chorioretinal atrophies.” (o’neil2019detailedretinalphenotype pages 6-7)

(Additional verbatim abstract text for Liu et al. 2024 and Liu & Hufnagel 2023 was not captured in the provided excerpts; therefore, only non-verbatim extraction is reported for those papers.) (liu2024neuropathytargetesterase pages 1-2, liu2023pnpla6disorderswhat’s pages 3-4)

Evidence gaps relative to the requested template

  • MONDO / Orphanet / ICD-10 / ICD-11 / MeSH identifiers: not present in retrieved full texts; would require direct querying of those databases.
  • Prevalence/incidence estimates: not provided in retrieved literature excerpts; current best quantitative evidence is published case counts.
  • Controlled treatment studies: no interventional trials specific to BNS identified in retrieved evidence.

References

  1. (deik2014compoundheterozygouspnpla6 pages 1-2): A. Deik, Brooke Johannes, J. Rucker, E. Sánchez, S. Brodie, E. Deegan, K. Landy, Y. Kajiwara, S. Scelsa, R. Saunders-Pullman, R. Saunders-Pullman, and C. Paisán-Ruiz. Compound heterozygous pnpla6 mutations cause boucher–neuhäuser syndrome with late-onset ataxia. Journal of Neurology, 261:2411-2423, Sep 2014. URL: https://doi.org/10.1007/s00415-014-7516-3, doi:10.1007/s00415-014-7516-3. This article has 44 citations and is from a domain leading peer-reviewed journal.

  2. (he2022identificationofnovel pages 1-2): Junyu He, Xin Liu, Liyi Liu, Shaohao Zeng, Shuanghong Shan, and Zhihong Liao. Identification of novel compound heterozygous variants of the pnpla6 gene in boucher–neuhäuser syndrome. Frontiers in Genetics, Feb 2022. URL: https://doi.org/10.3389/fgene.2022.810537, doi:10.3389/fgene.2022.810537. This article has 8 citations and is from a peer-reviewed journal.

  3. (liu2023pnpla6disorderswhat’s pages 3-4): James Liu and Robert B. Hufnagel. Pnpla6 disorders: what’s in a name? Ophthalmic Genetics, 44:530-538, Sep 2023. URL: https://doi.org/10.1080/13816810.2023.2254830, doi:10.1080/13816810.2023.2254830. This article has 15 citations and is from a peer-reviewed journal.

  4. (liu2024neuropathytargetesterase pages 1-2): James Liu, Yi He, Cara Lwin, Marina Han, Bin Guan, Amelia Naik, Chelsea Bender, Nia Moore, Laryssa A Huryn, Yuri V Sergeev, Haohua Qian, Yong Zeng, Lijin Dong, Pinghu Liu, Jingqi Lei, Carl J Haugen, Lev Prasov, Ruifang Shi, Hélène Dollfus, Petros Aristodemou, Yannik Laich, Andrea H Németh, John Taylor, Susan Downes, Maciej R Krawczynski, Isabelle Meunier, Melissa Strassberg, Jessica Tenney, Josephine Gao, Matthew A Shear, Anthony T Moore, Jacque L Duncan, Beatriz Menendez, Sarah Hull, Andrea L Vincent, Carly E Siskind, Elias I Traboulsi, Craig Blackstone, Robert A Sisk, Virginia Miraldi Utz, Andrew R Webster, Michel Michaelides, Gavin Arno, Matthis Synofzik, and Robert B Hufnagel. Neuropathy target esterase activity defines phenotypes among pnpla6 disorders. Brain : a journal of neurology, 147:2085-2097, May 2024. URL: https://doi.org/10.1093/brain/awae055, doi:10.1093/brain/awae055. This article has 10 citations.

  5. (liu2024neuropathytargetesterase pages 4-6): James Liu, Yi He, Cara Lwin, Marina Han, Bin Guan, Amelia Naik, Chelsea Bender, Nia Moore, Laryssa A Huryn, Yuri V Sergeev, Haohua Qian, Yong Zeng, Lijin Dong, Pinghu Liu, Jingqi Lei, Carl J Haugen, Lev Prasov, Ruifang Shi, Hélène Dollfus, Petros Aristodemou, Yannik Laich, Andrea H Németh, John Taylor, Susan Downes, Maciej R Krawczynski, Isabelle Meunier, Melissa Strassberg, Jessica Tenney, Josephine Gao, Matthew A Shear, Anthony T Moore, Jacque L Duncan, Beatriz Menendez, Sarah Hull, Andrea L Vincent, Carly E Siskind, Elias I Traboulsi, Craig Blackstone, Robert A Sisk, Virginia Miraldi Utz, Andrew R Webster, Michel Michaelides, Gavin Arno, Matthis Synofzik, and Robert B Hufnagel. Neuropathy target esterase activity defines phenotypes among pnpla6 disorders. Brain : a journal of neurology, 147:2085-2097, May 2024. URL: https://doi.org/10.1093/brain/awae055, doi:10.1093/brain/awae055. This article has 10 citations.

  6. (liampas2024twocasereports pages 1-5): Andreas Liampas, Paschalis Nicolaou, Christina Votsi, Anthi Georghiou, Kyproula Christodoulou, George A Tanteles, and Marios Pantzaris. Two case reports of a novel missense mutation in the pnpla6 gene in two siblings with chorioretinal dystrophy, hypogonadotropic hypogonadism, and cerebellar ataxia. Molecular biology reports, 51 1:590, Apr 2024. URL: https://doi.org/10.1007/s11033-024-09515-4, doi:10.1007/s11033-024-09515-4. This article has 0 citations and is from a peer-reviewed journal.

  7. (nanetti2022multifacetedandagedependent pages 9-10): Lorenzo Nanetti, Daniela Di Bella, Stefania Magri, Mario Fichera, Elisa Sarto, Anna Castaldo, Alessia Mongelli, Silvia Baratta, Silvia Fenu, Marco Moscatelli, Maria Teresa Bonati, Andrea Martinuzzi, Caterina Mariotti, and Franco Taroni. Multifaceted and age-dependent phenotypes associated with biallelic pnpla6 gene variants: eight novel cases and review of the literature. Frontiers in Neurology, Jan 2022. URL: https://doi.org/10.3389/fneur.2021.793547, doi:10.3389/fneur.2021.793547. This article has 18 citations and is from a peer-reviewed journal.

  8. (liu2023pnpla6disorderswhat’s pages 1-3): James Liu and Robert B. Hufnagel. Pnpla6 disorders: what’s in a name? Ophthalmic Genetics, 44:530-538, Sep 2023. URL: https://doi.org/10.1080/13816810.2023.2254830, doi:10.1080/13816810.2023.2254830. This article has 15 citations and is from a peer-reviewed journal.

  9. (deik2014compoundheterozygouspnpla6 pages 2-5): A. Deik, Brooke Johannes, J. Rucker, E. Sánchez, S. Brodie, E. Deegan, K. Landy, Y. Kajiwara, S. Scelsa, R. Saunders-Pullman, R. Saunders-Pullman, and C. Paisán-Ruiz. Compound heterozygous pnpla6 mutations cause boucher–neuhäuser syndrome with late-onset ataxia. Journal of Neurology, 261:2411-2423, Sep 2014. URL: https://doi.org/10.1007/s00415-014-7516-3, doi:10.1007/s00415-014-7516-3. This article has 44 citations and is from a domain leading peer-reviewed journal.

  10. (liu2023pnpla6disorderswhat’s pages 8-9): James Liu and Robert B. Hufnagel. Pnpla6 disorders: what’s in a name? Ophthalmic Genetics, 44:530-538, Sep 2023. URL: https://doi.org/10.1080/13816810.2023.2254830, doi:10.1080/13816810.2023.2254830. This article has 15 citations and is from a peer-reviewed journal.

  11. (nanetti2022multifacetedandagedependent pages 3-5): Lorenzo Nanetti, Daniela Di Bella, Stefania Magri, Mario Fichera, Elisa Sarto, Anna Castaldo, Alessia Mongelli, Silvia Baratta, Silvia Fenu, Marco Moscatelli, Maria Teresa Bonati, Andrea Martinuzzi, Caterina Mariotti, and Franco Taroni. Multifaceted and age-dependent phenotypes associated with biallelic pnpla6 gene variants: eight novel cases and review of the literature. Frontiers in Neurology, Jan 2022. URL: https://doi.org/10.3389/fneur.2021.793547, doi:10.3389/fneur.2021.793547. This article has 18 citations and is from a peer-reviewed journal.

  12. (o’neil2019detailedretinalphenotype pages 6-7): Erin O’Neil, Leona Serrano, Drew Scoles, Kayla E Cunningham, Grace Han, John Chiang, Jean Bennett, and Tomas S. Aleman. Detailed retinal phenotype of boucher-neuhäuser syndrome associated with mutations in pnpla6 mimicking choroideremia. Ophthalmic Genetics, 40:267-275, May 2019. URL: https://doi.org/10.1080/13816810.2019.1605392, doi:10.1080/13816810.2019.1605392. This article has 17 citations and is from a peer-reviewed journal.

  13. (liu2023neuropathytargetesterase pages 1-6): James Liu, Yi He, Cara Lwin, Marina Han, Bin Guan, Amelia Naik, Chelsea Bender, Nia Moore, Laryssa A. Huryn, Yuri Sergeev, Haohua Qian, Yong Zeng, Lijin Dong, Pinghu Liu, Jingqi Lei, Carl J. Haugen, Lev Prasov, Ruifang Shi, Hélène Dollfus, Petros Aristodemou, Yannik Laich, Andrea H. Németh, John Taylor, Susan Downes, Maciej Krawczynski, Isabelle Meunier, Melissa Strassberg, Jessica Tenney, Josephine Gao, Matthew A. Shear, Anthony T. Moore, Jacque L. Duncan, Beatriz Menendez, Sarah Hull, Andrea Vincent, Carly E. Siskind, Elias I. Traboulsi, Craig Blackstone, Robert Sisk, Virginia Utz, Andrew R. Webster, Michel Michaelides, Gavin Arno, Matthis Synofzik, and Robert B Hufnagel. Neuropathy target esterase activity predicts retinopathy among pnpla6 disorders. bioRxiv, Jun 2023. URL: https://doi.org/10.1101/2023.06.09.544373, doi:10.1101/2023.06.09.544373. This article has 1 citations.

  14. (NCT00671866 chunk 1): Neurotoxic Health Hazards of Long-Term Low-Level Exposure to Organophosphate (OP) Compounds in in Hula Valley. Shaare Zedek Medical Center. ClinicalTrials.gov Identifier: NCT00671866

  15. (liu2024neuropathytargetesterase pages 7-9): James Liu, Yi He, Cara Lwin, Marina Han, Bin Guan, Amelia Naik, Chelsea Bender, Nia Moore, Laryssa A Huryn, Yuri V Sergeev, Haohua Qian, Yong Zeng, Lijin Dong, Pinghu Liu, Jingqi Lei, Carl J Haugen, Lev Prasov, Ruifang Shi, Hélène Dollfus, Petros Aristodemou, Yannik Laich, Andrea H Németh, John Taylor, Susan Downes, Maciej R Krawczynski, Isabelle Meunier, Melissa Strassberg, Jessica Tenney, Josephine Gao, Matthew A Shear, Anthony T Moore, Jacque L Duncan, Beatriz Menendez, Sarah Hull, Andrea L Vincent, Carly E Siskind, Elias I Traboulsi, Craig Blackstone, Robert A Sisk, Virginia Miraldi Utz, Andrew R Webster, Michel Michaelides, Gavin Arno, Matthis Synofzik, and Robert B Hufnagel. Neuropathy target esterase activity defines phenotypes among pnpla6 disorders. Brain : a journal of neurology, 147:2085-2097, May 2024. URL: https://doi.org/10.1093/brain/awae055, doi:10.1093/brain/awae055. This article has 10 citations.

  16. (liu2024neuropathytargetesterase media cbbab372): James Liu, Yi He, Cara Lwin, Marina Han, Bin Guan, Amelia Naik, Chelsea Bender, Nia Moore, Laryssa A Huryn, Yuri V Sergeev, Haohua Qian, Yong Zeng, Lijin Dong, Pinghu Liu, Jingqi Lei, Carl J Haugen, Lev Prasov, Ruifang Shi, Hélène Dollfus, Petros Aristodemou, Yannik Laich, Andrea H Németh, John Taylor, Susan Downes, Maciej R Krawczynski, Isabelle Meunier, Melissa Strassberg, Jessica Tenney, Josephine Gao, Matthew A Shear, Anthony T Moore, Jacque L Duncan, Beatriz Menendez, Sarah Hull, Andrea L Vincent, Carly E Siskind, Elias I Traboulsi, Craig Blackstone, Robert A Sisk, Virginia Miraldi Utz, Andrew R Webster, Michel Michaelides, Gavin Arno, Matthis Synofzik, and Robert B Hufnagel. Neuropathy target esterase activity defines phenotypes among pnpla6 disorders. Brain : a journal of neurology, 147:2085-2097, May 2024. URL: https://doi.org/10.1093/brain/awae055, doi:10.1093/brain/awae055. This article has 10 citations.

  17. (liu2024neuropathytargetesterase media f1acab95): James Liu, Yi He, Cara Lwin, Marina Han, Bin Guan, Amelia Naik, Chelsea Bender, Nia Moore, Laryssa A Huryn, Yuri V Sergeev, Haohua Qian, Yong Zeng, Lijin Dong, Pinghu Liu, Jingqi Lei, Carl J Haugen, Lev Prasov, Ruifang Shi, Hélène Dollfus, Petros Aristodemou, Yannik Laich, Andrea H Németh, John Taylor, Susan Downes, Maciej R Krawczynski, Isabelle Meunier, Melissa Strassberg, Jessica Tenney, Josephine Gao, Matthew A Shear, Anthony T Moore, Jacque L Duncan, Beatriz Menendez, Sarah Hull, Andrea L Vincent, Carly E Siskind, Elias I Traboulsi, Craig Blackstone, Robert A Sisk, Virginia Miraldi Utz, Andrew R Webster, Michel Michaelides, Gavin Arno, Matthis Synofzik, and Robert B Hufnagel. Neuropathy target esterase activity defines phenotypes among pnpla6 disorders. Brain : a journal of neurology, 147:2085-2097, May 2024. URL: https://doi.org/10.1093/brain/awae055, doi:10.1093/brain/awae055. This article has 10 citations.

  18. (liu2024neuropathytargetesterase media d77bd8b8): James Liu, Yi He, Cara Lwin, Marina Han, Bin Guan, Amelia Naik, Chelsea Bender, Nia Moore, Laryssa A Huryn, Yuri V Sergeev, Haohua Qian, Yong Zeng, Lijin Dong, Pinghu Liu, Jingqi Lei, Carl J Haugen, Lev Prasov, Ruifang Shi, Hélène Dollfus, Petros Aristodemou, Yannik Laich, Andrea H Németh, John Taylor, Susan Downes, Maciej R Krawczynski, Isabelle Meunier, Melissa Strassberg, Jessica Tenney, Josephine Gao, Matthew A Shear, Anthony T Moore, Jacque L Duncan, Beatriz Menendez, Sarah Hull, Andrea L Vincent, Carly E Siskind, Elias I Traboulsi, Craig Blackstone, Robert A Sisk, Virginia Miraldi Utz, Andrew R Webster, Michel Michaelides, Gavin Arno, Matthis Synofzik, and Robert B Hufnagel. Neuropathy target esterase activity defines phenotypes among pnpla6 disorders. Brain : a journal of neurology, 147:2085-2097, May 2024. URL: https://doi.org/10.1093/brain/awae055, doi:10.1093/brain/awae055. This article has 10 citations.

  19. (liu2023neuropathytargetesterase pages 10-14): James Liu, Yi He, Cara Lwin, Marina Han, Bin Guan, Amelia Naik, Chelsea Bender, Nia Moore, Laryssa A. Huryn, Yuri Sergeev, Haohua Qian, Yong Zeng, Lijin Dong, Pinghu Liu, Jingqi Lei, Carl J. Haugen, Lev Prasov, Ruifang Shi, Hélène Dollfus, Petros Aristodemou, Yannik Laich, Andrea H. Németh, John Taylor, Susan Downes, Maciej Krawczynski, Isabelle Meunier, Melissa Strassberg, Jessica Tenney, Josephine Gao, Matthew A. Shear, Anthony T. Moore, Jacque L. Duncan, Beatriz Menendez, Sarah Hull, Andrea Vincent, Carly E. Siskind, Elias I. Traboulsi, Craig Blackstone, Robert Sisk, Virginia Utz, Andrew R. Webster, Michel Michaelides, Gavin Arno, Matthis Synofzik, and Robert B Hufnagel. Neuropathy target esterase activity predicts retinopathy among pnpla6 disorders. bioRxiv, Jun 2023. URL: https://doi.org/10.1101/2023.06.09.544373, doi:10.1101/2023.06.09.544373. This article has 1 citations.

  20. (liu2023pnpla6disorderswhat’s pages 4-6): James Liu and Robert B. Hufnagel. Pnpla6 disorders: what’s in a name? Ophthalmic Genetics, 44:530-538, Sep 2023. URL: https://doi.org/10.1080/13816810.2023.2254830, doi:10.1080/13816810.2023.2254830. This article has 15 citations and is from a peer-reviewed journal.

  21. (deik2014compoundheterozygouspnpla6 pages 11-12): A. Deik, Brooke Johannes, J. Rucker, E. Sánchez, S. Brodie, E. Deegan, K. Landy, Y. Kajiwara, S. Scelsa, R. Saunders-Pullman, R. Saunders-Pullman, and C. Paisán-Ruiz. Compound heterozygous pnpla6 mutations cause boucher–neuhäuser syndrome with late-onset ataxia. Journal of Neurology, 261:2411-2423, Sep 2014. URL: https://doi.org/10.1007/s00415-014-7516-3, doi:10.1007/s00415-014-7516-3. This article has 44 citations and is from a domain leading peer-reviewed journal.

Artifacts